Contrasting Cronos Group (NASDAQ:CRON) and Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) and Cronos Group (NASDAQ:CRON) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Earnings and Valuation

This table compares Corcept Therapeutics and Cronos Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41 million	16.83	$99.65 million	$0.42	282.24
Cronos Group	$146.59 million	8.10	-$9.45 million	$0.20	16.10

Corcept Therapeutics has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Corcept Therapeutics and Cronos Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Cronos Group	39.08%	4.85%	4.62%

Analyst Recommendations

This is a breakdown of recent ratings for Corcept Therapeutics and Cronos Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1	1	5	1	2.75
Cronos Group	0	2	3	0	2.60

Corcept Therapeutics presently has a consensus target price of $138.17, indicating a potential upside of 16.56%. Cronos Group has a consensus target price of $2.30, indicating a potential downside of 28.57%. Given Corcept Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Corcept Therapeutics is more favorable than Cronos Group.

Risk and Volatility

Corcept Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Summary

Corcept Therapeutics beats Cronos Group on 13 of the 15 factors compared between the two stocks.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.